ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag biotech neuroscience

Researchers in George Church&rsquo;s lab modified wild type ADK proteins (left) in <em >E.coli</em>, furnishing them with an nonstandard amino acid (nsAA) meant to biocontain the resulting bacterial strain.
A Pioneer of The Multiplex Frontier
Rashmi Shivni, Drug Discovery News | May 20, 2023 | 10 min read
George Church is at it again, this time using multiplex gene editing to create virus-proof cells, improve organ transplant success, and protect elephants.
Top 10 Innovations 2021
2021 Top 10 Innovations
The Scientist | Dec 1, 2021 | 10+ min read
The COVID-19 pandemic is still with us. Biomedical innovation has rallied to address that pressing concern while continuing to tackle broader research challenges.
Start It Up
Dan Cossins | Apr 1, 2013 | 8 min read
Young researchers who left the academic path to transform their bright ideas into thriving companies discuss their experiences, and how you can launch your own business.
Those We Lost in 2019
Ashley Yeager | Dec 30, 2019 | 6 min read
The scientific community said goodbye to Sydney Brenner, Paul Greengard, Patricia Bath, and a number of other leading researchers this year.
Clinical Trial Reversals Forcing Biotech Firms To Refine Strategy
Susan Dickinson | Sep 18, 1994 | 7 min read
Under pressure to reap return on investment, companies are seeking ways to ensure success in designing drug tests This past July, Synergen Inc. suspended clinical trials of its anti-inflammatory drug candidate, Antril--being tested to fight sepsis--for lack of efficacy. Faced with the setback to its $100 million-plus investment, the Boulder, Colo.-based biotech was forced to lay off more than half its work force and shut down two
Clinical Trial Reversals Forcing Biotech Firms To Refine Strategy
Susan Dickinson | Sep 18, 1994 | 7 min read
Under pressure to reap return on investment, companies are seeking ways to ensure success in designing drug tests This past July, Synergen Inc. suspended clinical trials of its anti-inflammatory drug candidate, Antril--being tested to fight sepsis--for lack of efficacy. Faced with the setback to its $100 million-plus investment, the Boulder, Colo.-based biotech was forced to lay off more than half its work force and shut down two
Top 10 Innovations 2013
The Scientist | Dec 1, 2013 | 10+ min read
The Scientist’s annual competition uncovered a bonanza of interesting technologies that made their way onto the market and into labs this year.
2020 Top 10 Innovations
The Scientist | Dec 1, 2020 | 10+ min read
From a rapid molecular test for COVID-19 to tools that can characterize the antibodies produced in the plasma of patients recovering from the disease, this year’s winners reflect the research community’s shared focus in a challenging year.
Notebook
Eugene Russo | Dec 5, 1999 | 7 min read
Contents Pivotal pump Leptin limbo Clue to obesity Biotech Web site Helping hand Mapping malaria Notebook Pictured above are pigmented bacterial colonies of Deinococcus radiodurans, the most radiation-resistant organism currently known. DEINO-MITE CLEANUP In 1956, investigators discovered a potentially invaluable cleanup tool in an unlikely place. A hardy bacterium called Deinococcus radiodurans unexpectedly thrived in samples of canned meat thought to be sterilized by gamma radiation. The b
2018 Top 10 Innovations
The Scientist | Dec 1, 2018 | 10+ min read
Biology happens on many levels, from ecosystems to electron transport chains. These tools may help spur discoveries at all of life's scales.

Run a Search

ADVERTISEMENT